File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bcp.2023.115491
- Scopus: eid_2-s2.0-85149737859
- PMID: 36898414
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo
Title | Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo |
---|---|
Authors | |
Keywords | Breast cancer Cancer recurrence Cancer stem cells Eriocalyxin B Gut microbiome Metastasis Natural products |
Issue Date | 2023 |
Citation | Biochemical Pharmacology, 2023, v. 210, article no. 115491 How to Cite? |
Abstract | Breast cancer is the most commonly diagnosed cancer among women, and its metastasis to distant organs accounts for the majority of death. Eriocalyxin B (Eri B), an ent-kaurane diterpenoid isolating from Isodon eriocalyx var. laxiflora, has previously been reported to have anti-tumor and anti-angiogenic effects in breast cancer. Here, we investigated the effect of Eri B on cell migration and adhesion in triple negative breast cancer (TNBC) cells, as well as aldehyde dehydrogenases 1 family member A1 (ALDH1A1) expression, colony- and sphere-formation in cancer stem cell (CSC) enriched MDA-MB-231 cells. The in vivo anti-metastatic activities of Eri B were determined in 3 different breast tumor-bearing mouse models. Our results indicated that Eri B inhibited TNBC cell migration and adhesion to extracellular matrix proteins, and also reduced ALDH1A1 expression and colony formation in CSC-enriched MDA-MB-231 cells. The metastasis-related pathways, such as epidermal growth factor receptor/ mitogen-activated protein kinase kinases 1/2/ extracellular regulated protein kinase signaling altered by Eri B was firstly shown in MDA-MB-231 cells. The potent anti-metastatic efficacies of Eri B were demonstrated in breast xenograft-bearing mice and syngeneic breast tumor-bearing mice. Gut microbiome analysis results revealed the change in the diversity and composition of microbiome after Eri B treatment, and the potential pathways that are involved in the anti-cancer efficacy of Eri B. In conclusion, Eri B was shown to inhibit breast cancer metastasis in both in vitro and in vivo models. Our findings further support the development of Eri B as an antimetastatic agent for breast cancer. |
Persistent Identifier | http://hdl.handle.net/10722/343412 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.365 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gou, Leilei | - |
dc.contributor.author | Yue, Grace Gar Lee | - |
dc.contributor.author | Lee, Julia Kin Ming | - |
dc.contributor.author | Puno, Pema Tenzin | - |
dc.contributor.author | Lau, Clara Bik San | - |
dc.date.accessioned | 2024-05-10T09:07:56Z | - |
dc.date.available | 2024-05-10T09:07:56Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Biochemical Pharmacology, 2023, v. 210, article no. 115491 | - |
dc.identifier.issn | 0006-2952 | - |
dc.identifier.uri | http://hdl.handle.net/10722/343412 | - |
dc.description.abstract | Breast cancer is the most commonly diagnosed cancer among women, and its metastasis to distant organs accounts for the majority of death. Eriocalyxin B (Eri B), an ent-kaurane diterpenoid isolating from Isodon eriocalyx var. laxiflora, has previously been reported to have anti-tumor and anti-angiogenic effects in breast cancer. Here, we investigated the effect of Eri B on cell migration and adhesion in triple negative breast cancer (TNBC) cells, as well as aldehyde dehydrogenases 1 family member A1 (ALDH1A1) expression, colony- and sphere-formation in cancer stem cell (CSC) enriched MDA-MB-231 cells. The in vivo anti-metastatic activities of Eri B were determined in 3 different breast tumor-bearing mouse models. Our results indicated that Eri B inhibited TNBC cell migration and adhesion to extracellular matrix proteins, and also reduced ALDH1A1 expression and colony formation in CSC-enriched MDA-MB-231 cells. The metastasis-related pathways, such as epidermal growth factor receptor/ mitogen-activated protein kinase kinases 1/2/ extracellular regulated protein kinase signaling altered by Eri B was firstly shown in MDA-MB-231 cells. The potent anti-metastatic efficacies of Eri B were demonstrated in breast xenograft-bearing mice and syngeneic breast tumor-bearing mice. Gut microbiome analysis results revealed the change in the diversity and composition of microbiome after Eri B treatment, and the potential pathways that are involved in the anti-cancer efficacy of Eri B. In conclusion, Eri B was shown to inhibit breast cancer metastasis in both in vitro and in vivo models. Our findings further support the development of Eri B as an antimetastatic agent for breast cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Biochemical Pharmacology | - |
dc.subject | Breast cancer | - |
dc.subject | Cancer recurrence | - |
dc.subject | Cancer stem cells | - |
dc.subject | Eriocalyxin B | - |
dc.subject | Gut microbiome | - |
dc.subject | Metastasis | - |
dc.subject | Natural products | - |
dc.title | Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.bcp.2023.115491 | - |
dc.identifier.pmid | 36898414 | - |
dc.identifier.scopus | eid_2-s2.0-85149737859 | - |
dc.identifier.volume | 210 | - |
dc.identifier.spage | article no. 115491 | - |
dc.identifier.epage | article no. 115491 | - |
dc.identifier.eissn | 1873-2968 | - |